Table 4 Associations of seven SNPs with platinum-based chemotherapy response in 395 NSCLC patients
Gene SNP | Genotype | Response | |||||||
|---|---|---|---|---|---|---|---|---|---|
Sensitive [cases (%)] | Resistant [cases (%)] | Additive model | Dominant model | Recessive model | |||||
OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | ||||
Total | 115 | 280 | |||||||
OCT2 | |||||||||
rs316003 | CC | 5 (4.3) | 13 (4.6) | 1.00 (0.68–1.47) | 0.992 | 1.01 (0.63–1.60) | 0.984 | 0.96 (0.33–2.81) | 0.939 |
CT | 38 (33.0) | 93 (33.2) | |||||||
TT | 65 (56.5) | 166 (59.3) | |||||||
rs316019 | TT | 2 (1.7) | 7 (2.5) | 1.08 (0.69–1.69) | 0.741 | 1.05 (0.63–1.75) | 0.840 | 1.51 (0.30–7.51) | 0.616 |
GT | 27 (23.5) | 68 (24.3) | |||||||
GG | 79 (68.7) | 197 (70.4) | |||||||
ABCB1 | |||||||||
rs1045642 | TT | 10 (8.7) | 45 (16.1) | 1.18 (0.85–1.65) | 0.323 | 1.05 (0.66–1.66) | 0.834 | 1.84 (0.89–3.83) | 0.102 |
CT | 57 (49.6) | 129 (46.1) | |||||||
CC | 45 (39.1) | 103 (36.8) | |||||||
ABCC2 | |||||||||
rs717620 | AA | 3 (2.6) | 9 (3.2) | 0.64 (0.43–0.96) | 0.031 | 0.54 (0.34–0.86) | 0.010 | 1.22 (0.32–4.68) | 0.772 |
AG | 46 (40.0) | 72 (25.7) | |||||||
GG | 62 (53.9) | 186 (66.4) | |||||||
rs2273697 | AA | 1 (0.9) | 1 (0.4) | 1.29 (0.73–2.28) | 0.391 | 1.35 (0.74–2.47) | 0.328 | 0.59 (0.04–9.55) | 0.709 |
AG | 16 (13.9) | 52 (18.6) | |||||||
GG | 97 (84.3) | 227 (81.1) | |||||||
rs3740066 | AA | 4 (3.5) | 10 (3.6) | 0.80 (0.54–1.19) | 0.271 | 0.72 (0.45–1.14) | 0.162 | 1.18 (0.36–3.90) | 0.790 |
AG | 42 (36.5) | 81 (28.9) | |||||||
GG | 65 (56.5) | 181 (64.6) | |||||||
MATE1 | |||||||||
rs2289669 | AA | 20 (17.4) | 65 (23.2) | 1.30 (0.93–1.81) | 0.126 | 1.32 (0.79–2.21) | 0.293 | 1.51 (0.86–2.66) | 0.155 |
AG | 58 (50.4) | 140 (50.0) | |||||||
GG | 30 (26.1) | 62 (22.1) | |||||||